Obstructive Jaundice — Written Clinical Reasoning

Part A — Diagnosis and the mechanism of obstructive jaundice

Diagnosis

The diagnosis is obstructive (surgical) jaundice from a pancreatic head mass, with the clinical and biochemical features of complete biliary obstruction: painless progressive jaundice, pale stools (acholic, from absence of intestinal stercobilin), dark urine (from conjugated bilirubin excreted by the kidney), pruritus, weight loss, and a markedly elevated CA 19-9. The cholestatic liver function pattern (conjugated hyperbilirubinaemia, ALP five times normal, elevated GGT, mildly raised transaminases) and the Courvoisier sign (palpable, non-tender gallbladder in a jaundiced patient) are both consistent with a malignant distal biliary obstruction [5].

The CT finding of a pancreatic head mass makes pancreatic ductal adenocarcinoma the leading diagnosis. Courvoisier sign has a low sensitivity (about 26 to 55 per cent) but a moderate-to-high specificity (83 to 90 per cent) for malignancy — its presence strongly suggests a malignant rather than a stone obstruction [5].

Pathophysiology — why the pattern arises

The obstruction prevents conjugated bilirubin from reaching the gut, so it refluxes into the bloodstream (conjugated hyperbilirubinaemia) and is filtered by the kidney (dark urine). The absence of intestinal stercobilin produces pale stools. The elevated ALP and GGT reflect the cholestatic injury to the hepatocytes and canaliculi. The GGT confirms the hepatic (rather than bone) origin of the ALP. [1]

Part B — Differential diagnosis and how to distinguish the causes

The differential diagnosis of obstructive jaundice is classified by the level of obstruction: [1]

Extrahepatic causes (ductal dilatation on imaging):

• Choledocholithiasis — the most common cause overall, but typically presents with biliary colic rather than painless progressive jaundice; the painless, progressive, deeply icteric picture with weight loss and Courvoisier sign points away from stones.
• Pancreatic head cancer — the leading diagnosis here, given the mass, the painless progressive jaundice, the weight loss, and the elevated CA 19-9.
• Cholangiocarcinoma — may produce an identical picture; the CT localisation to the pancreatic head (rather than the bile duct) and the elevated CA 19-9 favour pancreatic cancer, but EUS-FNA is needed for tissue.
• Ampullary cancer — arises at the ampulla; may cause intermittent jaundice and anaemia from GI blood loss; resected by Whipple with a better prognosis than pancreatic cancer.
• Biliary stricture — post-surgical, chronic pancreatitis, or PSC; the acute presentation and mass exclude this.
• Parasitic obstruction — Ascaris or liver flukes; the demographic and the mass exclude this.
• Mirizzi syndrome — a cystic duct stone compressing the common hepatic duct; excluded by the painless progressive picture and the mass. [1]

Intrahepatic cholestasis (no ductal dilatation): drugs (flucloxacillin, chlorpromazine, anabolic steroids, amoxicillin-clavulanate), PBC (middle-aged woman, AMA positive), PSC (young man with IBD), viral hepatitis, sepsis, Dubin-Johnson syndrome. These are excluded by the presence of a pancreatic head mass and ductal dilatation. [1]

The distinction is made by imaging: ultrasound first-line (assesses for stones and ductal dilatation), MRCP for the biliary tree, CT for the pancreatic mass and staging, and EUS-FNA for tissue diagnosis [2].

Part C — Imaging strategy and staging for resectability

The imaging strategy proceeds from the least invasive to the most definitive: [1]

1. Ultrasound (already performed) — the first-line modality, showing a pancreatic head mass.
2. Contrast-enhanced triple-phase CT (performed) — the key staging investigation. It confirms the mass, assesses for vascular encasement of the superior mesenteric artery, superior mesenteric vein, and portal vein (which renders the tumour locally advanced and unresectable), and screens for distant metastases (liver, peritoneum). The absence of vascular encasement and metastases in this patient classifies the tumour as resectable [3].
3. EUS-FNA — to obtain tissue for histological confirmation before committing to surgery or neoadjuvant therapy. EUS has the highest sensitivity for small pancreatic lesions and allows fine-needle aspiration with a sensitivity of 85 to 92 per cent and a specificity of 95 to 98 per cent for solid pancreatic lesions [8].
4. MRCP — may be performed to delineate the biliary anatomy and the exact level of obstruction, especially if the relationship to the ducts is unclear on CT.
5. Staging laparoscopy — may be performed immediately before laparotomy to exclude small peritoneal and liver metastases not seen on CT.

This patient has a resectable tumour (no vascular encasement, no metastases), making pancreaticoduodenectomy (Whipple) the treatment of choice with curative intent. [1]

Part D — The role and limitations of CA 19-9

CA 19-9 (carbohydrate antigen 19-9) has a sensitivity of approximately 79 to 81 per cent and a specificity of 82 to 90 per cent for pancreatic adenocarcinoma in symptomatic patients [4]. Its key limitations are:

• False-positive elevations in benign biliary obstruction, cholangitis, and cirrhosis — the markedly elevated level here, combined with the mass, is consistent with malignancy, but a lower elevation in a patient with cholangitis would not be diagnostic.
• False-negative results in the 5 to 10 per cent of the population who are Lewis-antigen-negative and constitutionally unable to synthesise CA 19-9 [4].

Because of these limitations, CA 19-9 is not a screening or diagnostic marker — the diagnosis is made by imaging and tissue. Its principal role is in monitoring treatment response and detecting recurrence: a failure to normalise after resection, or a rising trend during follow-up, suggests residual or recurrent disease. A pre-operative level above 100 U per mL may also correlate with a lower likelihood of resectability and a worse prognosis. [1]

Part E — Integrated management plan

Resection with curative intent

This patient has a resectable tumour and should be offered pancreaticoduodenectomy (Whipple procedure) — the only potentially curative treatment — followed by adjuvant chemotherapy (gemcitabine-based or FOLFIRINOX, depending on fitness and recovery). Surgery is the only chance of cure, but only 15 to 20 per cent of patients present with resectable disease [3].

The role of preoperative biliary drainage

The deeply jaundiced patient with a resectable tumour raises the question of preoperative biliary drainage to reduce the bilirubin before surgery. The landmark randomised trial by van der Gaag (NEJM 2010) showed that routine preoperative biliary drainage was associated with a higher rate of serious complications (74 versus 39 per cent) compared with early surgery, with many complications related to the stenting procedure itself [6]. Preoperative biliary drainage is therefore not routinely recommended for resectable pancreatic head cancer; it is reserved for cholangitis, when surgery must be delayed, or for patients undergoing neoadjuvant chemotherapy. In this patient with surgery planned within two weeks, I would proceed to surgery without routine drainage, provided the coagulation is corrected.

Pre-operative optimisation

• Correct the coagulopathy — check PT/INR; give vitamin K 10 mg intravenously to correct vitamin K malabsorption (the INR corrects if the hepatocytes are intact).
• Optimise nutrition and hydration.
• Assess fitness for major surgery — cardiac and respiratory evaluation, glycaemic control (new-onset diabetes is common). [1]

If unresectable or metastatic

If staging reveals locally advanced or metastatic disease, the approach shifts to palliation: biliary drainage by ERCP with a self-expanding metal stent (longer patency than plastic for the expected survival of months), palliative chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel), duodenal stenting for obstruction, celiac plexus neurolysis for pain, and early palliative care involvement. [1]

Part F — Excluding the mimics

Before committing to Whipple for presumed pancreatic adenocarcinoma, I would actively exclude: [1]

• Autoimmune pancreatitis (type 1, IgG4-related) — presents as painless obstructive jaundice with a pancreatic mass, mimicking cancer. The clues would be a diffusely sausage-shaped gland with a capsule-like rim, elevated serum IgG4, and other organ involvement; a dramatic steroid response is diagnostic. I would check serum IgG4 before surgery.
• Ampullary cancer — may be distinguished by EUS and the endoscopic appearance of the ampulla; it has a better prognosis and is resected by the same Whipple operation.
• Metastatic disease — staging laparoscopy immediately before laparotomy to exclude occult peritoneal or liver metastases that would render the operation futile. [1]

The tissue diagnosis from EUS-FNA, the CT staging, and the IgG4 level are the critical pre-operative investigations that prevent operating on a non-malignant or incurable lesion. [1]